Attached files
| file | filename |
|---|---|
| EX-99.1 - CHINA MEDICINE CORP | v209746_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 1, 2010
CHINA
MEDICINE CORPORATION
(Exact
name of registrant as specified in Charter)
|
Nevada
|
000-51379
|
51-0539830
|
|
(State of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
2/F,
Guangri Tower
No. 9
Siyounan Road 1st Street
Yuexiu
District
Guangzhou,
China 510600
(Address
of registrant’s principal executive office)
(8620)
8739-1718 and (8620) 8737-8212
(Registrant’s
telephone number, including area code)
Check the
appropriate box below in the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.
14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
7.01
|
Regulation
FD Disclosure
|
On
February 1, 2011, China Medicine Corporation, a Nevada Corporation (the “Company”) issued a
press release announcing that the Company has received a manufacturing license
from the Chinese Ministry of Agriculture for the Company’s proprietary
recombinant, Aflatoxin Detoxifizyme (rADTZ), which is used for removing
aflatoxins, a potential cancer causing agent, from food and animal
feed. In the press release, the Company also reaffirmed its
previously announced financial guidance for the year 2010 and provided full year
financial guidance for the year 2011. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
The
information contained herein and in the accompanying Exhibit 99.1 are being
furnished pursuant to “Item 7.01. Regulation FD Disclosure” and shall
not be incorporated by reference into any of the Company’s filings, whether made
before or after the date hereof, regardless of any general incorporation
language in such filing, unless expressly incorporated by specific reference to
such filing. The information in this report, including Exhibit 99.1
hereto, shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933.
|
Item
9.01
|
Financial
Statements and Exhibits
|
(d) Exhibits.
The
following is filed as an exhibit to this report:
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release of China Medicine Corporation, February 1,
2011.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CHINA
MEDICINE CORPORATION
|
|||
|
By:
|
/s/ Senshan Yang
|
||
|
Name:
|
Senshan
Yang
|
||
|
Title:
|
Chief
Executive Officer
|
||
Date:
February 1, 2011